MediWound Ltd.
MDWDHealthcare|Biotechnology|IL
$14.25
+0.92 (+6.90%)
Tangible Book / Share
$2.77
Cash / Share
$2.74
About
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Stock Price
-21.0%(1Y)
1M
+14.7%
3M
-1.0%
6M
-14.0%
YTD
-22.8%
1Y
-20.7%
3Y
+81.5%
5Y
-43.0%
Pipeline Summary
15 total trials1
Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
Completed: 8Recruiting: 2Approved: 1Terminated: 1Not Yet Recruiting: 2Unknown: 1
Active Trials (2)
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
NCT05157763Superficial Basal Cell Carcinoma
Phase 1Phase 2Recruiting
Enrollment: 32 participants
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
Phase 3Recruiting
Enrollment: 216 participants
Key Facts
Market Cap$184.0M
Employees121
CEOOfer Gonen
IPO DateMar 20, 2014
Beta0.14
52-Week Range$11.8 – $19.7
Avg Volume94,647
ExchangeNASDAQ
Websitemediwound.com
Ownership
Float74.5%
Shares Outstanding12.9M
Recent Insider Trades
Rubinstein SamuelBUY
Sep 1, 2026525 shares @ $12.62
Rubinstein SamuelSELL
Sep 1, 2026525 shares @ $12.72
Hess ShmuelOPTION EX.
Aug 26, 20265,000 shares @ $8.13
Hess ShmuelOPTION EX.
Aug 27, 202611,000 shares @ $8.13
Hess ShmuelSELL
Aug 27, 20261,979 shares @ $13.13
Peers
Recent News
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
Nov 5, 2026 · globenewswire.com
MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?
Nov 5, 2026 · zacks.com
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
Nov 3, 2026 · globenewswire.com
MediWound to Report Third Quarter 2026 Financial Results
Oct 29, 2026 · globenewswire.com
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis
Oct 9, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:21 AM